Alzheimer DiseaseNCT07122856
Predictive Factors for Initial MMSE Score and Rapid Decline in Alzheimer's Disease Patients
An observational study of Alzheimer Disease and Mini-Mental State Examination, run by Centre Hospitalier de Gonesse at 1 site in France.
Trial summary
This study looks at people with Alzheimer's disease to find out which factors are linked to their initial score on the Mini-Mental State Examination (MMSE) and which factors may predict a fast decline in their score over 12 months. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Alzheimer Disease, Mini-Mental State Examination, Cognitive Dysfunction
- How many people
- 100 participants
- Where
- 1 siteFrance
- Study dates
- 15 Sep 2025to 15 Mar 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: The study population consists of all patients who attended the Memory Clinic at CH Gonesse between July 2023 and July 2025. From this group, participants will be selected if they have a confirmed diagnosis of Alzheimer's disease (based on NIAA 2018 or IWG 2021 criteria) and have undergone at least two MMSE assessments spaced 12 months apart. Data will be extracted from medical records and registries within this hospital setting.
Who may be able to join
- Confirmed diagnosis of Alzheimer's disease according to NIAA 2018 or IWG 2021 criteria
- At least two MMSE evaluations spaced 12 months apart
- Follow-up at the Memory Clinic of CH Gonesse
Who cannot join
- Presence of other neurodegenerative diseases (e.g., Frontotemporal Dementia, Multiple System Atrophy, Vascular Dementia, LATE)
- Patient has moved out of the study area (outside the CH Gonesse territory)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
Centre Hospitalier de Gonesse
Gonesse, France
Abdullah Blakime, 01.34.53.24.64, coordination.rechercheclinique@ghtpdfr.fr
About this study
This study looks at people with Alzheimer's disease to find out which factors are linked to their initial score on the Mini-Mental State Examination (MMSE) and which factors may predict a fast decline in their score over 12 months. Researchers will review medical records from patients seen at the Memory Clinic of Gonesse Hospital and analyze information such as age, education, medical history, nutrition, mood, and caregiver burden. The goal is to better understand what influences early cognitive performance and how quickly it changes, to help improve patient care and planning.
- Conditions
- Alzheimer Disease, Mini-Mental State Examination, Cognitive Dysfunction, Neuropsychological Tests, Caregivers
- Medical subject headings
- Alzheimer Disease, Cognitive Dysfunction
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in MMSE Score Over 12 Months - measured as either a decrease of ≥3 points on the Mini-Mental State Examination [MeSH] or patient institutionalization within 12 months.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2025
- Study start15 Sep 2025 (estimated)
- Primary completion15 Mar 2026 (estimated)
- Study completion15 Mar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alzheimer DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier de Gonesse
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07122856
- Sponsor's protocol ID
- 0114_NEUROLOGIE_TARGET MMSE
- Status last verified
- Aug 2025
- First submitted
- 8 Aug 2025
- Last updated
- 14 Aug 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Predictive Factors for Initial MMSE Score and Rapid Decline in Alzheimer's Disease Patients
- ClinicalTrials.gov ID
- NCT07122856
- Acronym / sponsor ID
- 0114_NEUROLOGIE_TARGET MMSE
- Conditions
- Alzheimer Disease, Mini-Mental State Examination, Cognitive Dysfunction, Neuropsychological Tests, Caregivers
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Centre Hospitalier de GonesseUniversity, hospital or other
- Study start
- 15 Sep 2025 (estimated)
- Primary completion
- 15 Mar 2026 (estimated)
- Study completion
- 15 Mar 2026 (estimated)
- First posted
- 14 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study looks at people with Alzheimer's disease to find out which factors are linked to their initial score on the Mini-Mental State Examination (MMSE) and which factors may predict a fast decline in their score over 12 months. Researchers will review medical records from patients seen at the Memory Clinic of Gonesse Hospital and analyze information such as age, education, medical history, nutrition, mood, and caregiver burden. The goal is to better understand what influences early cognitive performance and how quickly it changes, to help improve patient care and planning.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- The study population consists of all patients who attended the Memory Clinic at CH Gonesse between July 2023 and July 2025. From this group, participants will be selected if they have a confirmed diagnosis of Alzheimer's disease (based on NIAA 2018 or IWG 2021 criteria) and have undergone at least two MMSE assessments spaced 12 months apart. Data will be extracted from medical records and registries within this hospital setting.
Key inclusion criteria (3 listed)
- Confirmed diagnosis of Alzheimer's disease according to NIAA 2018 or IWG 2021 criteria
- At least two MMSE evaluations spaced 12 months apart
- Follow-up at the Memory Clinic of CH Gonesse
Key exclusion criteria (2 listed)
- Presence of other neurodegenerative diseases (e.g., Frontotemporal Dementia, Multiple System Atrophy, Vascular Dementia, LATE)
- Patient has moved out of the study area (outside the CH Gonesse territory)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Change in MMSE Score Over 12 Months - measured as either a decrease of ≥3 points on the Mini-Mental State Examination [MeSH] or patient institutionalization within 12 months.
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2025.
Related trials for Alzheimer Disease
Recruiting
Automated Language Analysis in Neurodegenerative Diseases: Application of Artificial Intelligence Models
Alzheimer's Disease (AD), Frontotemporal Dementia (FTD)
Enrolling by invitationPhase 2
Tau PET Outcomes With Anti-amyloid Immunotherapies
Cognitive Impairment, Mild, Dementia, Mild
Active, not recruiting
Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial
Dementia, Cognitive Impairment
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Alzheimer Disease and Mini-Mental State Examination, run by Centre Hospitalier de Gonesse at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 14 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in MMSE Score Over 12 Months - measured as either a decrease of ≥3 points on the Mini-Mental State Examination [MeSH] or patient institutionalization within 12 months. (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2025.